Skip to content
Screener

D&A at other companies

Zoetis logo
ZoetisZTS
$119M-4.0%
Revvity logo
RevvityRVTY
$105.06M+7.8%
Elanco Animal Health Inc. logo
Elanco Animal Health Inc.ELAN
$139M+2.2%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$67.29M-43.7%
Opko Health logo
Opko HealthOPK
$18.97M-2.4%
Abbott logo
AbbottABT
$658M+56.7%

Segments

By segment

See full
Food Safety$26.5M+3.1%
Animal Safety$2.4M-35.1%

Other financials

Income statement

See full
Revenue$211.2M-4.4%
Gross profit$99.0M-10.2%
Operating income-$3.3M-161%
Net income-$17.0M-56.0%
EPS (diluted)-$0.08-60.0%

Balance sheet

See full
Cash & equivalents$159.9M+25.2%
Total debt$793.3M-11.2%
Total equity$2.1B-21.0%
Total assets$3.4B-16.8%

Cash flow

See full
Operating cash flow$22.7M+16.7%
CapEx$11.6M-64.7%
Free cash flow$11.1M+182%

Valuation

See full
Market cap$2.5B+125%
Enterprise value$3.13B+65.3%
P/S2.9×+1.6×

Profitability

See full
Gross margin45.2%-3.6pp
Operating margin-73.1%+77.7pp
Net margin-69.9%+30.8pp
FCF margin-14%

Returns & leverage

See full
Return on equity-25.6%+28.8pp
Debt / equity0.4×0.0×
Current ratio3.9×0.0×

Where this comes from

Reported directly by Neogen in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: Neogen’s 10-Q, filed April 9, 2026.

Filed
Apr 9, 2026, 4:03 PM EDT
Fiscal quarter
Q3 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-149599
Line itemNine months ended February 28, 2026Nine months ended February 28, 2025
Cash Flows provided by Operating Activities
Net income (loss)$3.4$(479.8)
Adjustments to reconcile net income (loss) to net cash from operating activities:
Depreciation and amortization86.989.2
Deferred income taxes(15.5)(33.1)
Share-based compensation10.413.0
Loss on disposal of property and equipment1.20.1
Amortization of debt issuance costs1.52.6

Item 1. Interim Condensed Consolidated Financial Statements

FAQ

What is Neogen's D&A?
Neogen (NEOG) reported D&A of $28.92M in Q4 2025.
How has Neogen's D&A changed year-over-year?
Neogen's D&A decreased by 1.5% year-over-year, from $29.35M to $28.92M.
What is the long-term trend for Neogen's D&A?
Over 3 years (2022 to 2025), Neogen's D&A has grown at a 71.5% compound annual growth rate (CAGR), from $23.69M to $119.48M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Ask your AI about Neogen's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude